

Title (en)

PHARMACEUTICAL COMPOSITION CONTAINING PROPOFOL, A CYCLODEXTRIN OR A CYCLODEXTRIN DERIVATIVE AND A PHARMACEUTICALLY ACCEPTABLE SALT

Title (de)

PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT PROPOFOL, EINEM CYCLODEXTRIN ODER EINEM CYCLODEXTRINDERIVAT UND EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ

Title (fr)

COMPOSITION PHARMACEUTIQUE CONTENANT DU PROPOFOL, UNE CYCLODEXTRINE OU UN DÉRIVÉ DE CYCLODEXTRINE ET UN SEL PHARMACEUTICALEMENT ACCEPTABLE

Publication

EP 4259214 A1 20231018 (FR)

Application

EP 21831313 A 20211210

Priority

- FR 2012996 A 20201210
- EP 2021085133 W 20211210

Abstract (en)

[origin: WO2022122992A1] The present invention relates to a pharmaceutical composition comprising propofol and at least one cyclodextrin and/or a cyclodextrin derivative. Characteristically, according to the invention, it further comprises at least one pharmaceutically acceptable salt, with the exception of basic and/or acidic pharmaceutically acceptable salts.

IPC 8 full level

A61K 47/69 (2017.01)

CPC (source: EP US)

A61K 31/05 (2013.01 - US); **A61K 47/02** (2013.01 - US); **A61K 47/6951** (2017.07 - EP US); **C08B 37/0015** (2013.01 - EP); **C08L 5/16** (2013.01 - EP)

Citation (search report)

See references of WO 2022122992A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

Designated validation state (EPC)

KH MA MD TN

DOCDB simple family (publication)

WO 2022122992 A1 20220616; AU 2021398541 A1 20230706; AU 2021398541 A9 20240530; CA 3201193 A1 20220616; EP 4259214 A1 20231018; FR 3117337 A1 20220617; FR 3117337 B1 20230428; US 2024050588 A1 20240215

DOCDB simple family (application)

EP 2021085133 W 20211210; AU 2021398541 A 20211210; CA 3201193 A 20211210; EP 21831313 A 20211210; FR 2012996 A 20201210; US 202118256719 A 20211210